Eidos Therapeutics Inc. appointed William Lis to its board, effective Dec. 4.

Lis recently was CEO and a director of biopharmaceutical company Portola Pharmaceuticals Inc.

Additionally, Hoyoung Huh stepped down as a director of Eidos.

Eidos Therapeutics is a clinical-stage biopharmaceutical company that develops drugs to treat diseases caused by the neurodegenerative disease transthyretin amyloidosis.